Close Menu
  • News
  • Medical
  • Technology
  • Nanomaterials
  • Research
  • Blog
    • Nasiol.com
  • Contact
    • Tech7685@gmail.com
What's Hot

Depositing quantum dots on corrugated chips improves photodetector capabilities

May 8, 2025

Ultrasonic nanocrystal surface modification restores stainless steel’s corrosion resistance

May 7, 2025

Structure dictates effectiveness and safety in nanomedicine, driving therapeutic innovation, say scientists

May 7, 2025
Facebook X (Twitter) Instagram
Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily
  • News
  • Medical
  • Technology
  • Nanomaterials
  • Research
  • Blog
    • Nasiol.com
  • Contact
    • Tech7685@gmail.com
Facebook X (Twitter) Instagram
Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily
Home»Medical»Discovery of nanoparticle-based drug delivery system could revolutionize schizophrenia treatment
Medical

Discovery of nanoparticle-based drug delivery system could revolutionize schizophrenia treatment

June 28, 2024No Comments3 Mins Read
Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
Discovery of nanoparticle-based drug delivery system could revolutionize schizophrenia treatment
Share
Facebook Twitter LinkedIn Pinterest Telegram Email

Schizophrenia is a complicated mental health disorder accompanied by wide range of symptoms such as hallucinations, impaired cognitive ability, and disorganized speech or behavior. It has been associated with anomalies in neurotransmission due to the imbalance of chemical neurotransmitters. Current treatment strategies against schizophrenia involve the administration of antipsychotic drugs, which can cause adverse effects and are associated with a high risk of cardiovascular disease. Moreover, in patients, response to therapeutic drugs is often inadequate as the blood-brain barrier (BBB), a protective barrier of cells, strictly regulates the movement of ions and molecules into the brain.

To overcome the hurdle of BBB and facilitate the transport of therapeutic drugs into brain tissue to treat schizophrenia, researchers have explored the applicability of receptor-mediated transcytosis (RMT) using low-density lipoprotein receptor-related protein 1 (LRP1). This research was conducted by team led by Associate Professor Eijiro Miyako from Japan Advanced Institute of Science and Technology (JAIST), included Prof. Yukio Ago from Hiroshima University, Prof. Shinsaku Nakagawa from Osaka University, Prof. Takatsugu Hirokawa from Tsukuba University, and Dr. Kotaro Sakamoto, Senior Principal Scientist at Ichimaru Pharcos Co., Ltd. Their study was published in JACS Au journal on June 20, 2024.

The researchers were inspired by previous findings which showed the interactions of vasoactive intestinal peptide receptor 2 (VIPR2) gene duplication in schizophrenia and their own discovery of a novel peptide, KS-133. The novel peptide, KS-133, has selective antagonist activity to VIPR2, leading to its downregulation. However, the major limitation associated with KS-133 was its poor permeability across BBB.

See also  Researchers develop cutting-edge smart bandages for improved wound healing

To facilitate the effective transport of KS-133 into the brain, they developed a brain-targeting peptide, KS-487, that could specifically bind to LRP1 and influence RMT. Finally, the researchers developed a novel nanoparticle-based drug delivery system (DDS) where KS-133 peptide was encapsulated with KS-487 targeting peptide and studied its efficacy in treating schizophrenia.

The administration of peptide formulations via the DDS resulted in the effective distribution of the drug in the brains of mice. Drug release profiles assessed by pharmacokinetic analysis confirmed the role of the brain-targeting peptide in transporting KS-133 into the brain. Furthermore, the efficacy of DDS was evaluated in mice with induced schizophrenia by elevated activation of VIPR2. Mice treated with KS-133/KS-487 nanoparticles showed significant improvement in cognitive functions during novel object recognition tests, which could be attributed to the inhibition of VIPR2.

Explaining the real-life applications and potential of their study, Dr. Miyako shares, “Existing drugs only have mechanisms involving neurotransmitter modulation, and their therapeutic effects are limited, especially for cognitive dysfunction. Thus, our peptide formulation could be used as a novel drug to restore cognitive dysfunction in schizophrenia.”

In summary, this study by Dr. Miyako and co-researchers provides preclinical evidence of a novel therapeutic strategy for targeting VIPR2 that could improve cognitive impairment in schizophrenia. “Going ahead, we will extend our study to involve cells and animal models, as well as human clinical trials, to confirm the efficacy and safety of this peptide formulation and promote its development as a new treatment for schizophrenia within 5 years,” concludes Dr. Miyako, optimistic about the long-term implications of their study.

See also  Nanotechnology-Enhanced Biomaterials: The Future of Osteoarthritis Treatment

We hope that the discovery and development of novel DDS utilizing bio-compatible peptides revolutionizes the treatment landscape of schizophrenia!

Source:

Japan Advanced Institute of Science and Technology

Journal reference:

Sakamoto, K., et al. (2024). Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia. JACS Au. doi.org/10.1021/jacsau.4c00311.

Source link

delivery discovery drug nanoparticlebased revolutionize schizophrenia System Treatment
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Modular protein adapter technology enables exosome-based precision drug delivery

May 6, 2025

Nanoparticle treatment combined with radiation therapy significantly improves glioblastoma survival in mice

May 3, 2025

Ultra-thin, flexible silicone nanosensor could have huge impact on brain injury treatment

April 22, 2025

The Evolving Role of Nanogels in Drug Delivery: New Developments

April 1, 2025

Nanogel drug delivery system shows promise for treating recurrent urinary tract infections

March 21, 2025

How activated gold nanoparticles reveal drug movement in the body

March 19, 2025

Comments are closed.

Top Articles

In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles

Technology

Inhalable nanoparticles could help treat chronic lung disease

News

Studying Electrical Properties -and More- with AFM

Editors Picks

Depositing quantum dots on corrugated chips improves photodetector capabilities

May 8, 2025

Ultrasonic nanocrystal surface modification restores stainless steel’s corrosion resistance

May 7, 2025

Structure dictates effectiveness and safety in nanomedicine, driving therapeutic innovation, say scientists

May 7, 2025

How Can Nanomaterials Be Programmed for Different Applications?

May 6, 2025
About Us
About Us

Your go-to source for the latest nanotechnology breakthroughs. Explore innovations, applications, and implications shaping the future at the molecular level. Stay informed, embrace the nano-revolution.

We're accepting new partnerships right now.

Facebook X (Twitter) Instagram Pinterest
Our Picks

Accelerating drug discovery with analytical R&D solutions

October 12, 2023

Improved ultrasound wireless charging for implantable biomedical devices

May 24, 2024

Scientists discover super sensor for the smallest scales

March 28, 2024

Subscribe to Updates

Get the latest creative Nano Tech news from Elnano.com

© 2025 Elnano.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.

Cleantalk Pixel